Multiple Myeloma Coverage from Every Angle

Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2

By: Julia Fiederlein
Posted: Friday, October 16, 2020

In the multicenter DREAMM-2 trial, treatment with the antibody-drug conjugate belantamab mafodotin seemed to confer deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma, according to Sagar Lonial, MD, of the Winship Cancer Institute, Atlanta, and colleagues. The 13-month follow-up analysis of the overall and subgroup populations was presented during the virtual edition of the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract MM-219).

Patients with relapsed or refractory multiple myeloma received either 2.5 (n = 95) or 3.4 (n = 99) mg/kg of single-agent belantamab mafodotin every 3 weeks. Patients with normal (at least 90 mL/min/1.73 m2), mildly impaired (60 to < 90 mL/min/1.73 m2), and moderately impaired (30 to < 60 mL/min/1.73 m2) estimated glomerular filtration rates were eligible for enrollment. Those with t(4;14), t(14;16), 17p13del, or 1q21+ abnormalities were considered to be at high risk.

Patients with mild and moderate renal impairment seemed to achieve clinical responses. The objective response rates were similar among patients with normal renal function (2.5 mg/kg: 37%; 3.4 mg/kg: 35%), and mild (2.5 mg/kg: 33%; 3.4 mg/kg: 40%) and moderate (2.5 mg/kg: 33%; 3.4 mg/kg: 27%) renal impairment. Keratopathy, thrombocytopenia, and anemia were among the most frequently reported grade 3 and 4 adverse events in patients with renal impairment.

Similar efficacy outcomes were observed in patients with high-risk and standard-risk cytogenetics; these outcomes also seemed to be consistent with those observed in the overall population. The most common adverse event in patients with high-risk or standard-risk cytogenetics was keratopathy. Overall, the rates of anemia and thrombocytopenia seemed to be higher in patients with high-risk cytogenetics than in patients with standard-risk cytogenetics.

“Single-agent belantamab mafodotin represents an important new treatment option for patients with heavily pretreated relapsed or refractory multiple myeloma, including those with high-risk cytogenetics and renal impairment,” the investigators concluded.

Disclosure: No information regarding conflicts of interest was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.